Author: Ravi Shankar

Leo International Precision Health AG: Mr Leo Wang, Disposal

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them,
19. Oct 2026 / 23:55 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name

Title	Mr
First name	Leo
Last name	Wang

2. Reason for the notification

a) Position / status

Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

Leo International Precision Health AG

b) LEI

529900R5095181VD8H48

4. Details of the transaction(s)

a) Description of the financial instrument

Type	Share
ISIN	DE0005490601

b) Nature of the transaction

Disposal

c) Price(s) and volume(s)

Price(s)	Volume(s)
0.0054 EUR	22,882.00 EUR

d) Aggregated information

Price	Aggregated volume
0.0054 EUR	22,882.00 EUR

e) Date of the transaction (CET/CEST)

14.10.2026

f) Place of the transaction

Outside a trading venue

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has granted an aggregate of 1,600,000 stock options to purchase common shares of the Company to officers of the Company pursuant to the Company’s Omnibus Equity Incentive Plan (the “Plan”).

The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the date of grant. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly instalments over the subsequent 36 months, subject to the terms of the Plan.

The grant of these stock options remains subject to the approval of the TSX Venture Exchange.

About Conavi Medical

Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/.

Forward looking information

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact

Mark Quick, Chief Financial Officer | 416-483-0100
Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com

• Record Quarterly Total Revenue of $1.6 billion
• Adjusted EBITDAR⁽¹⁾ Margin of 24%
• Operating Margin of 12%
• Liquidity⁽²⁾ to LTM Revenue ratio at 21%

MEXICO CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO, “Aeroméxico” or the “Company”) today reported unaudited consolidated financial results for the three months ended September 30, 2026 (“3Q26”). These results are based on information available to us as of the date of this earnings release and are not a comprehensive statement of our financial results for the period presented. The Company has used the U.S. dollar, its functional currency, as the presentation currency for its consolidated financial statements. All figures are expressed in millions of U.S. dollars unless otherwise indicated.

Andrés Conesa, Chief Executive Officer stated: “Aeroméxico delivered another strong quarter, with record revenue and a double-digit operating margin of 12%. Demand remained healthy, driven primarily by strong international markets, premium revenue growth, and continued momentum in our loyalty program. Despite jet fuel prices reaching historic highs during the quarter, targeted revenue initiatives, disciplined cost management, and moderated capacity deployment enabled us to offset the impact of higher fuel costs. Looking ahead, demand trends remain constructive, and we expect fourth quarter revenue to grow by approximately 15% year over year. As we resume growth with discipline, we expect to unlock further operating leverage and continue enhancing profitability.”

OPERATING & FINANCIAL HIGHLIGHTS 3Q26

• Capacity, measured in available seat miles (ASMs), increased by 1.3% year-over-year.
• Total revenue reached $1.6 billion; a 13.6% increase compared to the same period of 2025.
• Total fuel expense amounted to $469.0 million, a 57.6% year-over-year increase, equivalent to an increase of $171.5 million.
• Adjusted EBITDAR⁽¹⁾ totaled $389.2 million, with a 24.0% margin.
• Operating income totaled $189.6 million, with an 11.7% margin.
• Total adjusted net debt to EBITDAR⁽¹⁾ ended the quarter at 2.1x. 
• Liquidity⁽²⁾ totaled $1.2 billion, equivalent to 20.7% of last-twelve-month revenues.

4Q26 & FULL YEAR OUTLOOK

Indicator	4Q26 Guidance	FY26 Guidance
Total capacity (ASMs) YoY (%)	~ +7.0% to +8.0%	~ +2.0% to +3.0%
Total Revenue YoY (%)	~ +14.0% to +16.0%	~ +13.5% to +14.5%
Adjusted EBITDAR Margin (1)	~ 19.5% to 21.5%	~ 21.5% to 22.5%
Operating Income Margin	~ 7.5% to 9.5%	~ 8.5% to 9.5%

The Company’s updated outlook for the remainder of the year reflects the October 16, 2026 fuel forward curve and continued cost pressures, while maintaining the assumption of a healthy demand environment. Revenue generation in the fourth quarter is expected to remain healthy, supported by sustained demand trends and disciplined commercial execution. Higher utilization of our existing fleet is expected to support planned capacity growth, strengthen operating leverage, and keep cost per ASM excluding fuel (CASM-Ex) broadly stable year-over-year in 4Q26.

The guidance reflects an average all-in fuel price of approximately USD $4.5 per gallon for the fourth quarter. It also assumes exchange rate of $18.0 Mexican pesos per U.S. dollar for the fourth quarter.

KEY FINANCIAL AND OPERATING HIGHLIGHTS FOR THE THIRD QUARTER

	Three Months Ended September 30			Nine Months Ended September 30
Key Financial KPIs	2026	2025	Var.	2026	2025	Var.
Total revenue (USD millions)	1,619	1,425	13.6%	4,440	3,923	13.2%
Adjusted EBITDAR(1)(USD millions)	389	442	(11.9)%	989	1,171	(15.5)%
Adjusted EBITDAR margin(1)(% of revenue)	24.0%	31.0%	(7.0)p.p.	22.3%	29.9%	(7.6)p.p.
Total operating income (loss) (USD millions)	190	253	(25.0)%	399	625	(36.1)%
Operating income margin (% of revenue)	11.7%	17.7%	(6.0)p.p.	9.0%	15.9%	(6.9)p.p.
Key Operating Indicators	2026	2025	Var.	2026	2025	Var.
Total ASMs (millions)	9,395	9,277	1.3%	27,248	27,054	0.7%
Passengers (‘000)	6,161	6,362	(3.2)%	17,966	18,419	(2.5)%
Total revenue / ASM (USD cents)	17.2	15.4	12.2%	16.3	14.5	12.4%
Total cost / ASM (USD cents)	15.1	12.7	19.4%	14.8	12.2	21.4%
Total cost excluding fuel / ASM (USD cents)	10.1	9.5	7.1%	10.1	9.0	12.1%
Foreign Exchange*	2026	2025	Var.	2026	2025	Var.
Average	17.22	18.67	(7.7)%	17.40	19.57	(11.1)%
*Source: Company with information from Banxico. Figures may not sum to total due to rounding.

THIRD QUARTER 2026 RESULTS

Income Statement Discussion

Revenue

Total revenue for the third quarter of 2026 reached $1.6 billion, a 13.6% year-over-year increase, setting a quarterly record for the Company. Revenue growth was primarily driven by higher passenger revenue, particularly across international markets, as the Company implemented targeted pricing actions to mitigate the impact of higher fuel costs. This performance reflects the Company’s ability to pass-through the impact of elevated fuel prices, supported by disciplined network deployment, and complementary revenues, including loyalty and cargo.

During the third quarter of 2026, Aeroméxico updated its loyalty program breakage — the first such alignment since 2018— to better reflect current member activity and long-term program trends. This update resulted in the recognition of $48.7 million in revenue for the period alongside an adjustment to our deferred liability. More importantly, this updated approach establishes the baseline that will drive sustained, positive growth in our annual loyalty revenue moving forward.

Our premium revenue⁽³⁾ mix reached 42% of passenger-related revenue, 1 p.p. above 3Q25, supported by continued upsell of higher-yield products and ancillary services. The Company’s fare segmentation and premium cabin cross-sell initiatives continue to broaden customer choice while enhancing the strength and resilience of our revenue base. Cargo revenues grew 15.8%, driven by the implementation of various commercial initiatives.

Capacity increased 1.3% year over year, in line with the Company’s guidance. The Company continued to optimize its network through disciplined capacity deployment, selectively allocating capacity toward higher-yielding international markets and adjusting flight frequencies to align supply with demand.

Total revenue per Available Seat Mile (“TRASM”) reached 17.2¢, representing a 12.2% year-over-year increase. This growth was primarily driven by higher passenger revenue, particularly across international markets, as well as increases in cargo revenue, loyalty, and other commercial revenues. 

	Three Months Ended September 30			Nine Months Ended September 30
Total revenue (USD million)	2026	2025	Var.	2026	2025	Var.
Domestic	541	507	6.7%	1,556	1,418	9.7%
International	1,078	918	17.4%	2,884	2,505	15.1%
Total revenue	1,619	1,425	13.6%	4,440	3,923	13.2%
Figures may not sum to total due to rounding.

Operating Expenses

In 3Q26, total operating expenses—including fuel, labor, maintenance, passenger and aircraft services, aircraft leases, selling, general and administrative expenses, depreciation and amortization and other expenses—reached $1.4 billion, an increase of 21.9% compared to 3Q25. The increase was primarily driven by higher fuel costs, as prices remained elevated throughout the quarter, with benchmark prices peaking above $4.7 per gallon in September—the highest level since the Middle East conflict began in March. Fuel expense increased by approximately $171.5 million year-over-year, exceeding the level contemplated in the Company’s 3Q26 guidance by approximately $93.0 million.

Fuel cost per gallon⁽⁴⁾ increased by 60.6% compared to 3Q25, averaging US$4.0 per gallon in 3Q26 compared to US$2.5 per gallon in 3Q25. Fuel consumption decreased by 1.8% year-over-year, while fuel burn per ASM (liters of fuel consumed per ASM) decreased by 3.1%, mainly due to a more efficient fleet mix. 

Excluding fuel, operating expenses rose 9.8% year over year. This rise primarily reflected the continued strength of the Mexican peso, which increased the dollar-denominated cost of certain peso-based expenses, as well as inflationary pressures on wages, salaries, and benefits, higher distribution costs due to increased sales, and increased depreciation and amortization associated to fleet growth.

CASM-Ex was 10.1¢ in 3Q26, representing an increase of 7.1% compared with the same period in 2025. The increase primarily reflected the impact of the stronger Mexican peso and inflationary pressures, partially offset by continued cost discipline and operating efficiencies.

Adjusted EBITDAR⁽¹⁾ and Operating Income

Adjusted EBITDAR⁽¹⁾ amounted to $389.2 million, representing a strong 24.0% margin. These results reflect solid revenue performance and the Company’s ability to offset the year-over-year increase in fuel costs in absolute terms.

Operating income for the third quarter was $189.6 million, representing a robust 11.7% operating margin. While profitability was pressured by a higher-than-expected fuel environment and the expected increase in non-fuel operating costs, this performance underscores the strength of the Company’s business model and its ability to preserve healthy profitability despite these headwinds.

Net Financing Cost

Net financing costs increased by 7.7% compared to the same period in 2025, mainly driven by higher financial expenses arising from lease obligations associated with fleet expansion.

Net Income

Net income in 3Q26 totaled $40.6 million, with a 2.5% margin.

BALANCE SHEET AND CASH FLOW

As of September 30, 2026, Aeroméxico generated $541.7 million in net cash from operating activities, supporting both its planned investments and deleveraging program. Despite elevated fuel prices and related cost pressures, this strong operating cash generation enabled the Company to maintain its capital expenditure plan while continuing to reduce financial debt. During the third quarter, the Company repaid $7.2 million of financial debt, further reducing its outstanding obligations.

As of September 30, 2026, Aeroméxico reported cash and cash equivalents of $965.1 million, an increase of $31.0 million compared with the same period in the previous year. During the quarter, the Company renewed and upsized its revolving credit facility from $200.0 million to $250.0 million. Including the revolving credit facility, total liquidity reached $1.2 billion, representing 20.7% of last-twelve-month revenue.

OPERATING FLEET

During 3Q26, Grupo Aeroméxico received one Boeing 787-9 aircraft. Grupo Aeroméxico’s operating fleet was comprised of 170 aircraft as of September 30, 2026, with an average age of 9.1 years.

Operating Fleet	4Q25	1Q26	2Q26	3Q26
B-737-800	34	34	34	34
B-737 MAX 8	45	45	47	47
B-737 MAX 9	30	30	30	30
B-787-8	8	8	8	8
B-787-9	14	15	16	17
Aeroméxico	131	132	135	136
E-190	34	34	34	34
Aeroméxico Connect	34	34	34	34
Grupo Aeroméxico	165	166	169	170

Footnotes

1. See Annex A for the definition of Aeroméxico’s non-IFRS measures and a reconciliation to the nearest IFRS measure.
2. Liquidity is defined as cash and cash equivalents, and the revolving credit facility.
3. Premium revenue mix consists of revenue from premium products and services above Basic / Classic coach cabin products. Ratio is calculated based on total passenger revenue.
4. Equivalent to 1.05 USD per liter in 3Q26 and 66¢ per liter in 3Q25.

3Q26 EARNINGS CALL INFORMATION
Date	Tuesday, October 20, 2026
Time	10:00 a.m. ET (NY) / 8:00 a.m. CT (CDMX)
Webcast Link	https://edge.media-server.com/mmc/p/uh5yer4m/
Participant Listening*	https://register-conf.media-server.com/register/BIce2042e6b22d45d587f891c8178a6137

*Participants can complete the online registration form and upon registering will receive the dial-in info and a unique PIN to join the call.

About Grupo Aeroméxico

Grupo Aeroméxico, S.A.B. de C.V. is a holding company whose subsidiaries are engaged in commercial aviation in Mexico and the promotion of passenger loyalty programs. Aeroméxico, Mexico’s global airline, has its main operations center in Terminal 2 of the Mexico City International Airport. Its destination network has reach in Mexico, the United States, Canada, Central America, South America, Asia and Europe. The Group’s current operating fleet includes Boeing 787 and 737 aircraft, as well as the latest generation Embraer 190. Aeroméxico is a founding partner of SkyTeam, an alliance that celebrates 26 years and offers connectivity in more than 170 countries, through the 18 partner airlines. Aeroméxico created and implemented a Health and Hygiene Management System (SGSH) to protect its clients and collaborators at all stages of its operation.www.aeromexico.com / www.skyteam.com

Forward Looking Statements

This press release contains certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act, that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. We use words such as “believe,” “anticipate,” “plan,” “expect,”, “intend,” “target,” “estimate,” “project,” “predict,” “guidance,” “forecast,” “guideline,” “should” and other similar expressions to identify forward-looking statements, but they are not the only way we identify such statements. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this release. Important factors that could cause such differences include, but are not limited to: external risks, including health threats, accidents, global instability, security breaches, terrorism and natural disasters; global geopolitical conflicts, particularly those that impact the price of jet fuel; Mexican and international economic conditions, as well as seasonality, on customer travel behavior; the current U.S.’s administration tariffs on the Company’s costs and the actions of other governmental authorities in Mexico, the U.S. and other countries; fuel market volatility; the Company’s capacity to fulfill the Company’s fixed obligations, obtain financing and/or maintain liquidity; the Company’s capacity to retain and attract key personnel and other professionals, and the Company’s labor relations with employees; the Company’s reliance on few aircraft manufacturers and other third-party providers; the Company’s aircraft utilization rate and aircraft maintenance costs; changes in landing charges, airport access fees and inadequate airport infrastructure; consumer protection restrictions; dependence on the Company’s main hub, MEX; air traffic congestion; the competitive environment in the aviation industry, including those arising from non-air travel substitutes; sanctions and compliance with anti-corruption, anti-money laundering, anti-drug trafficking and other ethical rules and standards; reliance on partnerships and alliances and challenges in entering into new ones; and other factors described in “Risk Factors” of the annual report on Form 20-F filed with the SEC on April 30, 2026. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Grupo Aeroméxico, S.A.B. de C.V. and Subsidiaries
Consolidated Statements of Profit or Loss and other Comprehensive Income (Unaudited)
	Three Months Ended September 30			Nine Months Ended September 30
	2026	2025	Var. %	2026	2025	Var. %
Revenues:
Passenger	1,414	1,299	8.8%	3,935	3,557	10.6%
Air cargo	90	78	15.8%	252	230	9.7%
Other	115	48	NA	252	135	86.4%
Total revenue	1,619	1,425	13.6%	4,440	3,923	13.2%
Operating expenses:
Jet-fuel	469	297	57.6%	1,278	858	48.9%
Wages, salaries and benefits	325	299	8.6%	949	829	14.5%
Maintenance	66	64	2.9%	212	167	26.8%
Aircraft, communications and traffic services	182	166	9.4%	508	451	12.7%
Passenger services	46	41	11.0%	127	112	13.5%
Travel agent commissions	30	26	15.0%	80	70	15.5%
Selling and administrative	104	92	12.5%	284	258	10.0%
Aircraft leasing	3	5	(27.1)%	11	13	(9.4)%
Depreciation and amortization	196	184	6.6%	579	537	7.8%
Impairment (reversal)	—	—	NA	—	(4)	NA
Other (income) loss, net	8	(2)	NA	13	13	(0.2)%
Share of gain on equity accounted investees, net of tax	—	(2)	NA	—	(5)	NA
Total operating expenses	1,429	1,172	21.9%	4,040	3,297	22.5%
Total operating income	190	253	(25.0)%	399	625	(36.1)%
Finance income (cost):
Net finance cost	(142)	(132)	7.7%	(407)	(391)	3.9%
Income before income tax	48	121	(60.6)%	(7)	234	NA
Income tax (benefit)	7	24	(70.4)%	(1)	47	NA
Net income (loss) for the period	41	97	(58.1)%	(6)	187	NA
Figures may not sum to total due to rounding.

Grupo Aeroméxico, S.A.B. de C.V. and Subsidiaries
Earnings per Share (Unaudited)
	Three Months Ended September 30		Nine Months Ended September 30
(In thousands of U.S. dollars, except for income per share)	2026	2025	2026	2025
Income for the year	41	97	(6)	187
Earnings per share from continuing operations
Basic income per share (US dollars)	0.03	0.07	0.00	0.14
Diluted income per share (US dollars)	0.03	0.07	0.00	0.14
Basic income (loss) per ADS (US dollars)	0.28	0.72	(0.04)	1.38
Diluted income (loss) per ADS (US dollars)	0.28	0.71	(0.04)	1.37
Figures may not sum to total due to rounding.

Grupo Aeroméxico, S.A.B. de C.V. and Subsidiaries
Consolidated Statements of Financial Position (Unaudited)
	(USD Millions)
	September 30, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	965	1,024
Trade and other receivables	854	700
Due from related parties	9	3
Prepayments and deposits	65	78
Inventories	194	174
Total current assets	2,088	1,980
Non-current assets:
Property and equipment, including right-of-use	3,724	3,674
Other non–current assets	1,584	1,539
Total non-current assets	5,308	5,213
Total assets	7,396	7,193
Liabilities
Current liabilities:
Loans and borrowings, including leases	475	451
Others	2,865	2,645
Total current liabilities	3,339	3,096
Non-current liabilities:
Loans and borrowings, including leases	3,588	3,604
Others	1,063	1,085
Total non-current liabilities	4,651	4,689
Total liabilities	7,991	7,785
Equity
Total equity (deficit)	(595)	(592)
Total equity and liabilities	7,396	7,193
Figures may not sum to total due to rounding.

Grupo Aeroméxico, S.A.B. de C.V. and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)
	(USD Millions)
	Nine Months Ended September 30
	2026	2025	Var. ($)
Cash flow from operating activities:
Income for the period	(6)	187	(193)
Income tax expense	(1)	47	(48)
Depreciation and amortization	579	537	42
Other non-cash adjustments	298	280	18
	869	1,051	(182)
Changes in current assets & liabilities, net	(328)	(483)	155
Trade and other receivables	(129)	(1)	(128)
Trade and other payables	(10)	(197)	188
Air traffic liability	95	(36)	131
Others, net	(41)	(29)	(12)
Interest paid	(243)	(219)	(24)
Net cash from operating activities	542	568	(26)
Cash flow from investing activities:
Acquisition of properties and equipment (including major maintenance)	(258)	(213)	(46)
Other investing activities, net	(12)	4	(15)
Net cash used in investing activities	(270)	(209)	(61)
Cash flow from financing activities:
Payments of lease liabilities	(304)	(269)	(35)
Repayment of loans	(24)	(93)	68
Other financing activities, net	—	65	(65)
Net cash used in financing activities	(328)	(297)	(31)
Effect of exchange rate fluctuations on cash held	(3)	30	(33)
Net increase (decrease) in cash and cash equivalents	(59)	92	(151)
Cash and cash equivalents:
At beginning of the period	1,024	842	182
At end of the period	965	934	31
Figures may not sum to total due to rounding.

FINANCIAL AND OPERATIONAL INDICATORS
	Three Months Ended September 30			Nine Months Ended September 30
Financial Indicators	2026	2025	Var.	2026	2025	Var.
Total revenue	1,619	1,425	13.6%	4,440	3,923	13.2%
Passenger revenue	1,414	1,299	8.8%	3,935	3,557	10.6%
Adjusted EBITDAR(1)	389	442	(11.9)%	989	1,171	(15.5)%
Adjusted EBITDAR margin(1)(% revenue)	24.0%	31.0%	(7.0)p.p.	22.3%	29.9%	(7.6)p.p.
Total operating income (loss)	190	253	(25.0)%	399	625	(36.1)%
Operating income margin (% of revenue)	11.7%	17.7%	(6.0)p.p.	9.0%	15.9%	(6.9)p.p.
Net income (loss)	41	97	(58.1)%	(6)	187	NA
Net income (loss) margin (% of revenue)	2.5%	6.8%	(4.3)p.p.	(0.1)%	4.8%	(4.9)p.p.
Operating Indicators	2026	2025	Var.	2026	2025	Var.
Total ASMs (millions)	9,395	9,277	1.3%	27,248	27,054	0.7%
Total RPMs (millions)	8,296	8,184	1.4%	23,403	23,119	1.2%
Load factor on scheduled flights (%)	88.3%	88.2%	0.1p.p.	85.9%	85.5%	0.4p.p.
Passengers (‘000)	6,161	6,362	(3.2)%	17,966	18,419	(2.5)%
On-Time departure performance within 15 min.(%)	90.9%	91.5%	(0.6)p.p.	91.0%	92.0%	(1.0)p.p.
Total liters of fuel (‘000)	445,237	453,547	(1.8)%	1,300,904	1,319,298	(1.4)%
Yield (USD cents)(2)	15.3	13.9	10.6%	14.9	13.5	10.3%
Total revenue / ASM (USD cents)	17.2	15.4	12.2%	16.3	14.5	12.4%
Passenger revenue / ASM (USD cents)(2)	13.5	12.2	10.7%	12.8	11.5	10.8%
Total cost / ASM (USD cents)	15.1	12.7	19.4%	14.8	12.2	21.4%
Total cost excluding fuel / ASM (USD cents)	10.1	9.5	7.1%	10.1	9.0	12.1%
Other Indicators	2026	2025	Var.	2026	2025	Var.
Fuel cost per gallon (USD cents)	3.99	2.48	60.6%	3.71	2.46	50.8%
FX close(3)	17.84	18.38	(2.9)%	17.84	18.38	(2.9)%
FX average(3)	17.22	18.67	(7.7)%	17.40	19.57	(11.1)%
Figures may not sum to total due to rounding. 1) See Annex A for the definition of Aeroméxico’s non-IFRS measures and a reconciliation to the nearest IFRS measure. 2) Estimated as passenger revenues (excluding ancillaries) divided by total RPMs. 3) Source: Company with information from Banxico.

Annex A on Non-IFRS Financial Measures

In addition to disclosing financial results prepared in accordance with IFRS, the Company discloses information regarding Adjusted EBITDAR, Adjusted EBITDAR Margin, Adjusted Net Debt and Net Leverage Ratio, which are non-IFRS measures. The Company believes that these measures are useful indicators of its operational performance. These known performance measurements in the aviation industry are frequently used by investors, stock analysts and others who are interested in comparing the operational performance of companies in their industry.

The Company defines Adjusted EBITDAR as profit or loss for the period before income tax expense (benefit), depreciation and amortization, net finance cost, and impairment (reversal), before aircraft leasing expense, in light of the non-recurring nature of this item. The Company considers Adjusted EBITDAR to be solely a valuation metric, not a performance metric. The Company defines Adjusted EBITDAR Margin as Adjusted EBITDAR divided by total revenue for the period. The Company defines Adjusted Net Debt as total loan and borrowings, including leases, minus cash and cash equivalents. The Company defines Net Leverage Ratio as Adjusted Net Debt Ratio divided by Adjusted EBITDAR for the period.

All of the above-mentioned non-IFRS financial measures have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of the Company’s results as reported under IFRS. Some of these limitations are: (i) they do not reflect the Company’s cash expenditures, or future requirements for capital expenditures or contractual commitments; (ii) they do not reflect changes in, or cash requirements for, its working capital needs; (iii) they do not reflect the Company’s cash requirements necessary to service interest or principal payments on the Company’s debt; (iv) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and they do not reflect any cash requirements for such replacements; (v) they do not adjust for all non-cash income or expense items that are reflected in the Company’s consolidated statements of profit or loss and other comprehensive income; (vi) they do not reflect the impact of all non-recurring items; and (vii) other companies in the Company’s industry may calculate these measures, or similarly titled measures, differently than the Company does, limiting their usefulness as comparative measures.

Reconciliations of each of these historical measures, and to the extent applicable, forward-looking measures to the most directly comparable IFRS measure are below. No reconciliation of the forecasted amounts of Adjusted EBITDAR Margin, as incrementally adjusted, for fiscal 2026 is included in this release because we are unable to quantify certain amounts that would be required to be included in the corresponding IFRS measure without unreasonable efforts, due to high variability and complexity with respect to estimating certain forward-looking amounts, and we believe such reconciliation would imply a degree of precision that would be confusing or misleading to investors.

	Three Months Ended September 30			Nine Months Ended September 30
Adjusted EBITDAR reconciliation	2026	2025	Var.	2026	2025	Var.
Profit (loss) for the period	41	97	(58.1)%	(6)	187	NA
(+) Income tax expense (benefit)	7	24	(70.4)%	(1)	47	NA
(+) Depreciation and amortization(1)	196	184	6.6%	579	537	7.8%
(+) Net finance cost	142	132	7.7%	407	391	3.9%
(+) Impairment (reversal)	—	—	NA	—	(4)	NA
(+) Aircraft leasing(2)	3	5	(27.1)%	11	13	(9.4)%
Adjusted EBITDAR(3)	389	442	(11.9)%	989	1,171	(15.5)%

Figures may not sum to total due to rounding.
¹⁾ Depreciation and amortization expense as presented in our profit or loss.
²⁾ Aircraft leasing is comprised of short-term rentals of flight equipment, including subject to PBH period.
³⁾ Adjusted EBITDAR is a non-IFRS measure and has limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of the Company’s results as reported under IFRS.

Adjusted net debt reconciliation	As of September 30, 2026	As of December 31, 2025
Total loans and borrowings, including leases	4,063	4,055
(-) Cash and cash equivalents	965	1,024
Adjusted net debt(1)	3,098	3,031

Figures may not sum to total due to rounding.
¹⁾ Adjusted Net Debt is a non-IFRS measure and has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of the Company’s results as reported under IFRS.

Net leverage ratio reconciliation (Adjusted net debt / Last twelve months adjusted EBITDAR)	As of September 30, 2026	As of December 31, 2025
Adjusted net debt(1)	3,098	3,031
Last twelve months adjusted EBITDAR(1)	1,491	1,672
Net leverage ratio(1)	2.1x	1.8x

Figures may not sum to total due to rounding.
¹⁾ Adjusted Net Debt, Adjusted EBITDAR and Net Leverage Ratio are non-IFRS measures and have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of the Company’s results as reported under IFRS.

CONTACT:		Investor Relations		aminvestorrelations@aeromexico.com
		Corporate Communications		amcomunicacioncorporativa@aeromexico.com

Transaction Expected to Add More Than $10 Million to Stockholders’ Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities

LITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos” or the “Company”) today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. (“SOD Sciences” or “SOD”) and a 50% undivided co-ownership interest in SOD’s pseudohypoxia early‑warning test, the “Primed Cell for Chronic Disease” test. In exchange, Vivos issued to SOD 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. No cash consideration was paid by either party. Through the joint marketing arrangement to be negotiated with SOD following closing and SOD’s marketing relationship with Florida based CLIA-certified lab American Health Associates (“AHA”), Vivos also expects to obtain the opportunity to test and treat AHA’s more than 325,000 existing patients at approximately 3,000 assisted living facilities and nursing homes, many of whom are believed to be at elevated risk for OSA and for chronic diseases such as diabetes, cancer, and cardiovascular disease, subject to the negotiation and execution of definitive agreements and to final approval of the bankruptcy court in AHA’s pending bankruptcy proceeding.

“Today Vivos became more than a healthcare company just treating sleep apnea,” said R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos. “We expect this transaction to add more than $10 million to our stockholders’ equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease. With more than 2,600 sleep centers in the country and SOD’s channel partners behind us, we intend to take that test nationwide, and our FDA-cleared appliances treat the obstructive sleep apnea that may be contributing to the condition the test is designed to identify.”

The transaction at a glance

• $10,380,000 of expected additional stockholders’ equity. Vivos issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000, convertible at a fixed conversion price of $0.15 per share into up to 80,000,000 shares of common stock, subject to a 19.99% exchange cap pending stockholder approval and a 4.99% beneficial ownership limitation (which the holder may increase to 9.99% on 61 days’ notice). The conversion price represented a premium to the closing price of Vivos’ common stock on the date the agreement was signed. Vivos expects to record the SOD interest and the test interest as assets at fair value and to classify the preferred stock in permanent stockholders’ equity, resulting in an expected increase in stockholders’ equity of more than $10 million, subject to completion of the final valuation and review by the Company’s independent registered public accounting firm.
• Half of a new test. Vivos owns an undivided 50% interest in the pseudohypoxia test and related intellectual property and is entitled to 50% of the contribution margin on sales of the test through any channel, by either company. Contribution margin should not be equated with revenue, net income or cash flow.
• A potential national market. Following closing, Vivos and SOD expect to negotiate a separate agreement under which SOD’s ReBalU Protocol would be marketed to Vivos customers and U.S. sleep-testing centers on a 50/50 economic sharing basis. The Company believes the pseudohypoxia test could expand its diagnostic and therapeutic services offerings to the more than 2,600 sleep testing centers nationwide, to the more than 2,500 multi-location cardiology medical practices in the U.S., and to the approximately 3,000 assisted living centers and nursing homes currently serviced by AHA.
• New channels for Vivos products. Under the joint marketing agreement to be negotiated following closing, SOD would market Vivos’ testing and device products through its AHA marketing relationship and its existing relationship with Cleveland Clinic Weston, with Vivos expected to retain the revenue from its sleep testing services and 80% of the contribution margin on sales of Vivos products through those channels (with SOD receiving 20%).

Management believes the closing of this transaction has the potential to be a transformational event for Vivos that could reshape and expand the Company’s market and services offerings to hundreds of thousands of new patients at high risk for OSA and related chronic diseases. SOD Sciences is expected to provide Vivos with new diagnostic and therapy products that Vivos believes to be highly synergistic with its core FDA-cleared and proprietary OSA treatment methods and technologies, subject to clinical validation and applicable regulatory requirements.

In addition, the close collaboration with SOD Sciences is expected to provide Vivos with access to established distribution channels, such as Cleveland Clinic Weston (Florida) and AHA, subject to the negotiation and execution of definitive agreements. Vivos management expects to meet later this week with senior clinical and administrative leadership at both the Cleveland Clinic (Florida) and AHA to begin working through execution logistics and timelines.

Management believes that, if definitive agreements with AHA are executed and the channel is implemented as contemplated, the AHA channel could represent a meaningful, potentially multi-million dollar, OSA sleep testing revenue opportunity for Vivos beginning in 2027, with limited capital and staffing outlays from Vivos. Management also sees potential additional revenue from Vivos oral appliance product sales and other related treatments. Remote patient monitoring and patient turnover in the target facilities may represent further revenue and profit opportunities that the Company would seek to quantify once the relationship is underway and further data is collected.

Any potential revenue or margin from the pseudohypoxia test or related products will depend on clinical validation, regulatory status, channel execution, testing volume, realized pricing, and the costs allocated under the definitive agreements. This release does not establish that the test predicts any conditions. Vivos’ oral-appliance FDA clearances do not extend to the test.  Any potential revenue or margin from the AHA relationship remains subject to entry into definitive agreements and bankruptcy court approval.

Nasdaq Stockholders’ Equity Requirement

As previously disclosed, in April 2026 the Company received a notice from The Nasdaq Stock Market LLC that it did not satisfy the minimum stockholders’ equity requirement of $2.5 million for continued listing under Nasdaq Listing Rule 5550(b)(1). The Company believes that, giving effect to the transaction and the expected classification of the Series C Convertible Preferred Stock in permanent stockholders’ equity, its stockholders’ equity exceeds that requirement. Any determination that the Company has regained compliance is subject to Nasdaq’s review, and no assurance can be given that Nasdaq will concur or that the Company will be able to maintain compliance with this or any other continued listing requirement.  

While the Company believes it has regained compliance with the stockholders’ equity requirement as a result of the closing of the transaction described herein, Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic report the Company does not evidence compliance, that it may be subject to delisting.

About Vivos Therapeutics

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. For more information, visit www.vivos.com.

About SOD Sciences

SOD Sciences, Inc. is a precision-health company and the developer of the ReBalU Protocol, which combines genetic and biomarker testing with a nutrition-based program and follow-up testing. SOD is also developing applications of its platform related to pseudohypoxia, including the pseudohypoxia early-warning test.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: the expected increase in the Company’s stockholders’ equity and the anticipated accounting treatment of the Series C Convertible Preferred Stock and the acquired interests; the Company’s compliance with Nasdaq continued listing requirements; the negotiation and execution of the joint marketing agreement, the sleep-center agreement and definitive agreements with AHA and Cleveland Clinic Weston; the Company’s ability to test and treat patients through the AHA channel, including the outcome of AHA’s bankruptcy proceeding; the clinical utility, validation, regulatory status and commercial potential of the pseudohypoxia test and the ReBalU Protocol; anticipated revenue, margin and profit opportunities; the stockholder approval to be sought under Nasdaq Listing Rule 5635(a); and the expected benefits of the transaction. Words such as “expects,” “believes,” “intends,” “potential,” “could,” “may,” “would,” “contemplated” and similar expressions identify forward-looking statements.

These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including, without limitation, the risks that: (i) the Company’s independent registered public accounting firm or Nasdaq reaches conclusions regarding the accounting treatment of the transaction or the Company’s stockholders’ equity that differ from those anticipated; (ii) the Company does not regain or maintain compliance with Nasdaq’s continued listing requirements; (iii) the joint marketing agreement, the sleep-center agreement and definitive agreements with AHA and Cleveland Clinic Weston are not executed on the anticipated terms or at all; (iv) AHA does not emerge from bankruptcy, or the bankruptcy court does not approve the arrangements contemplated, on the anticipated timetable or at all; (v) the pseudohypoxia test does not achieve clinical validation, regulatory clearance or market acceptance; (vi) the anticipated revenue, margin and other benefits of the transaction are not realized; (vii) stockholder approval of the issuance of common stock upon conversion of the Series C Convertible Preferred Stock in excess of the exchange cap is not obtained; (viii) conversion of the Series C Convertible Preferred Stock results in dilution to existing stockholders; and (ix) the other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor and media contacts

Vivos Therapeutics, Inc.: Investor Relations, investors@vivoslife.com

SOD Sciences, Inc.: info@sodsciences.com

Toronto, Ontario, Oct. 19, 2026 (GLOBE NEWSWIRE) — Belgravia Hartford Capital Inc. (CSE: BLGV) (OTC: BLGVF) (FRA: ECA) (the “Corporation” or “Belgravia”) announces that it intends to complete a consolidation of its issued and outstanding common shares (the “Shares“) on the basis of one new Share (a “Post-consolidated Share“) for every ten currently outstanding Shares (the “Consolidation“). The Shares will continue to be listed on the CSE under the symbol “BLGV” and the OTCQB under the symbol “BLGVF”.

Completion of the Consolidation is subject to approval by the Canadian Securities Exchange (the “CSE“). The effective date of the Consolidation will be announced in a subsequent news release.

It is anticipated that the Consolidation will reduce the number of outstanding Shares from 137,720,837 Shares to approximately 13,772,083 Post-consolidated Shares, subject to adjustment for rounding. The Board of Directors of the Company believes that the consolidation of the Shares will both enhance the marketability of the Company as an investment and better position the Company to raise funds necessary to execute the Company’s business plan.

No fractional Post-consolidated Shares will be issued as a result of the Consolidation. As required under the Business Corporations Act (British Columbia), any fractional Shares remaining after the Consolidation that are less than one half of a Share will be cancelled and any fractional Shares that are at least one half of a Share will be rounded up to one whole Share.

The exercise price and number of Shares of the Company, issuable upon the exercise of outstanding warrants, will be proportionally adjusted upon the implementation of the proposed Consolidation in accordance with the terms thereof.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Belgravia Hartford Capital Inc.

Belgravia Hartford Capital Inc. is an investment issuer listed for trading on the Canadian Securities Exchange and OTCQB, focused on the technology and finance sectors of the Bitcoin ecosystem. The Company’s focus, as set out in its 2018 Investment Policy, includes cryptocurrencies, artificial intelligence, media, and digital streaming opportunities. Belgravia invests in a portfolio of private and public companies located in jurisdictions governed by the rule of law. Belgravia and its investments are considered high-risk holdings and may expose shareholders to significant volatility and losses. For more legal disclaimer and information, please visit www.belgraviahartford.com. Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements and Disclaimer

This press release contains forward-looking statements regarding Belgravia and the Consolidation. Forward-looking statements are based on current expectations and are subject to risks, uncertainties, regulatory requirements, technical dependencies, product validation, market conditions, commercial execution risk, digital asset market volatility, and other factors that may cause actual results to differ materially.

For further information: Please Contact: Mehdi Azodi, President & CEO, Belgravia Hartford Capital Inc., (416) 779- 3268, mazodi@blgv.ca CO: Belgravia Hartford Capital Inc. 

Broadens Our Existing Footprint in Carolina Markets

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that its subsidiary, Century Fire Protection (“Century”), has recently acquired A&A Fire Protection, LLC (“A&A”). Jake Gilstrap, President of A&A, will continue to lead day-to-day operations and retain a minority equity interest. Terms of the transaction were not disclosed.

Headquartered in Greenville, South Carolina and founded in 1977, A&A is a leading provider of fire sprinkler design, installation, inspection and repair services to a broad range of commercial end-markets across South Carolina as well as regions spanning western North Carolina and north Georgia.

“This acquisition furthers Century’s strategy of enhancing its scale and broadening its client base in existing markets,” said Richard Deeb, CEO of Century. “We are excited to be partnering with the A&A team and look forward to collectively deepening our fire sprinkler and alarm capabilities in the growing Carolina markets.”

ABOUT FIRSTSERVICE CORPORATION

FirstService Corporation is a North American leader in the property services sector, serving its customers through two industry-leading service platforms: FirstService Residential, North America’s largest manager of residential communities; and FirstService Brands, one of North America’s largest providers of essential property services delivered through individually branded company-owned operations and franchise systems.

FirstService generates more than $5.5 billion in annual revenues and has approximately 30,000 employees across North America. With significant insider ownership and an experienced management team, FirstService has a long-term track record of creating value and superior returns for shareholders. The Common Shares of FirstService trade on the NASDAQ and the Toronto Stock Exchange under the symbol “FSV”, and are included in the S&P/TSX 60 Index. More information is available at www.firstservice.com.

FORWARD-LOOKING STATEMENTS

This press release includes or may include forward-looking statements. Much of this information can be identified by words such as “expect to,” “expected,” “will,” “estimated” or similar expressions suggesting future outcomes or events. FirstService believes the expectations reflected in such forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results, performance or achievements contemplated in the forward-looking statements. Such factors include: (i) general economic and business conditions, which will, among other things, impact demand for FirstService’s services and the cost of providing services; (ii) the ability of FirstService to implement its business strategy, including FirstService’s ability to acquire suitable acquisition candidates on acceptable terms and successfully integrate newly acquired businesses with its existing businesses; (iii) changes in or the failure to comply with government regulations; and (iv) other factors which are described in FirstService’s annual information form for the year ended December 31, 2025 under the heading “Risk factors” (a copy of which may be obtained at www.sedarplus.ca) and Annual Report on Form 40-F filed with the United States Securities and Exchange Commission (a copy of which may be obtained at www.sec.gov), and subsequent filings (which factors are adopted herein). Forward-looking statements contained in this press release are made as of the date hereof and are subject to change. All forward-looking statements in this press release are qualified by these cautionary statements. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this press release to reflect subsequent information, events, results or circumstances or otherwise.

COMPANY CONTACT:

Jeremy Rakusin
CFO
FirstService Corporation
(416) 960-9566

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Blossom Gold Inc. (“Blossom Gold” or the “Company”) (TSX: BGAU) is pleased to announce that its common shares have been approved for trading on the OTCQX Best Market in the United States under the ticker symbol “BGAUF,” effective October 20, 2026. The Company’s common shares will continue to trade on the Toronto Stock Exchange under the symbol “BGAU.”

“Joining the OTCQX Best Market is an important step in broadening Blossom Gold’s shareholder base and improving trading access for our U.S.-based investors,” said Rick Winters, Chief Executive Officer of Blossom Gold. “As we continue to advance the Rosebud Project toward development, this trading platform gives U.S. investors a more direct and efficient way to participate in our story alongside our existing TSX shareholders.”

The OTCQX Best Market is the highest-level market of OTC Markets Group’s markets and is reserved for established, investor-focused companies that meet high financial standards and demonstrate compliance with applicable securities laws. Trading on OTCQX is intended to provide Blossom Gold with improved visibility and accessibility among U.S. investors, including access to real-time quotes and market data through popular U.S. financial websites and brokerage platforms.

U.S. investors will be able to trade Blossom Gold shares through most U.S. brokerage firms during regular U.S. market hours. Real-time price quotations for the Company’s shares will be available at www.otcmarkets.com under the symbol “BGAUF.”

About Blossom Gold Inc.

Blossom Gold is a Canadian-based precious metals exploration and development company that recently began trading on the TSX under the symbol BGAU. Blossom Gold acquired the Rosebud Project in connection with the TSX-listing and will be focused on the exploration and development of the project. The Rosebud Project includes the former Rosebud Mine, where mining was conducted from 1997 through 2000 by the Rosebud Mining Company, a Newmont-Hecla joint venture, using underground mining methods where the mine operated at a cut-off grade of approximately 0.2 opt Au (6.8 gAu/t), when gold prices ranged from US$250 to US$350/oz; with mined material truck-hauled approximately 120 miles to an existing Newmont oxide mill for processing.

The current vision for the Rosebud Project is to evaluate the remaining higher-grade mineralization and the surrounding larger volume of lower grade mineralization as a potential open pit mining operation with on-site, heap-leach processing and recovery of gold and silver. The Rosebud Project currently hosts an Inferred Mineral Resource of 70.755 million tons grading 0.62gAu/t (0.018opt Au) and 6.49gAg/t (0.189opt Ag) for 1.28 million ounces of gold and 13.4 million ounces of silver. The mineral resource estimate was open pit constrained using long term gold and silver prices of US$2,500 and US$35 per ounce respectively. The deposit is open in all directions.

Further details on Blossom and the Rosebud Project, including the technical report titled “Mineral Resource Estimate for the Rosebud Property, Pershing County, NV, USA” by Northern Lights Mining LLC, with a report date of December 17, 2025 and an effective date of November 1, 2025, can be found under the Company’s profile on SEDAR+ at www.sedarplus.com and the Company’s website at www.blossomgold.com.

For further information, please contact:

Brandon Throop
Vice President, Corporate Development & Investor Relations
Direct: 1-647-646-7824
Email: bthroop@blossomgold.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements other than statements of historical facts included in this news release constitute forward-looking information, including but not limited to statements regarding the Company’s plans, prospects and business strategies, including its senior leadership team, its core drilling program and advancing the Rosebud Project, permitting and commencing construction, and its vision regarding the Rosebud Project. Terminology such as “plan”, “expect”, “schedule”, “estimate”, “forecast”, “intend”, “anticipate”, “believe”, “may” or “will” and similar expressions identify forward-looking information. By identifying such information in this manner, Blossom is alerting the reader that such information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Blossom to be materially different from those expressed or implied by such information. In addition, in connection with the forward-looking information contained in this news release, Blossom has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the inability of Blossom to achieve any one or more of the key catalysts on the timeline expected, or at all, and any changes in the development of the business of Blossom, as well as those risk factors more generally set out in Blossom’s AIF, which is available under Blossom’s profile on SEDAR+ at www.sedarplus.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein. Although Blossom believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information are reasonable, undue reliance should not be placed on such information, and no assurance or guarantee can be given that such forward-looking information will prove to be accurate. The forward-looking information contained in this news release is provided as of the date of this news release, and Blossom does not undertake to update any forward-looking information that is contained or referenced herein, except in accordance with applicable Canadian securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7a358677-c512-4b2d-8a46-dd365fbfb90d

A combination of SmartGateway and Xtract One Gateway Systems to Protect High School, Middle School Campuses, and District Events

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced that Willis Independent School District in Willis, Texas has approved a contract for approximately USD $1 million for the deployment of 15 Xtract One systems across its campuses and district facilities. The Willis ISD Board of Trustees voted 5-0 to approve the purchase, which includes 11 Xtract One Gateways and 4 SmartGateways, with installation scheduled to complete within the next few months.

In addition to the district implementing additional security as part of a longer-term strategy, Willis ISD cited Manor ISD‘s experience with Xtract One as a key factor in the decision, with Manor ISD reporting the successful deployment and achievement of the intended objectives of the program. “Our board came together quickly and decisively to do what’s right for our students and our community,” said Dr. Kimberly James, Superintendent of Willis ISD. “We are committed to adding layers of protection that allow our students to focus on learning in an environment where they feel safe.”

“Willis ISD made a thoughtful and thorough decision under an accelerated schedule,” said Peter Evans, CEO of Xtract One Technologies. “Selecting systems that distinguish between everyday student items and genuine threats, that can move between campuses and events, and that allow students to walk through at a normal pace with their backpacks, without unnecessary systems like X-ray machines, reflects exactly the kind of program a district should build. We’re proud to support Willis ISD and its community.”

Xtract One Gateway is designed for school environments where students carry laptops, tablets, water bottles, binders, and personal electronics as part of their daily routine. The system identifies and classifies specific threat objects while accurately distinguishing them from everyday items, without requiring students to stop, remove items, or submit to bag searches. Security staff receive specific alerts identifying what triggered and exactly where on the individual’s body, enabling secondary screening that is fast, targeted, and minimally disruptive to the school day.

SmartGateway, deployed for larger gatherings including sporting events, is designed for high-throughput environments where individuals carry low volumes of personal belongings. Both systems connect to Xtract One View, the centralized cloud management platform that gives district security leadership real-time visibility into system performance across all locations.

The portability of both systems was a key consideration in the district’s selection. Units can be repositioned between locations and deployed for events without permanent installation, giving Willis ISD operational flexibility across its campuses and facilities throughout the school year.

Willis ISD joins a growing number of Texas school districts deploying Xtract One’s AI-powered weapons detection technology under the state’s HB 2 school safety funding framework. Manor ISD, whose deployment was referenced directly in the Willis ISD board presentation, has expanded Xtract One Gateway across approximately half of its 15 campuses following initial deployment at its high school campuses.

To learn more, visit www.xtractone.com.

About Willis Independent School District
Willis Independent School District serves the Willis, Texas community in Montgomery County, providing K-12 education across multiple campuses including Willis High School, middle school campuses, and district facilities. The district is committed to providing a safe, supportive learning environment for all students. For more information, visit www.willisisd.org.

About Xtract One
Xtract One Technologies is a leading technology-driven provider of threat detection and security solutions leveraging AI to deliver seamless and secure experiences. The Company makes unobtrusive weapons and threat detection systems that are designed to assist facility operators in prioritizing- and delivering improved “Walk-right-In” experiences while enhancing safety. Xtract One’s innovative portfolio of AI-powered Gateway solutions excels at allowing facilities to discreetly screen and identify weapons and other threats at points of entry and exit without disrupting the flow of traffic. With solutions built to serve the unique market needs for schools, hospitals, arenas, stadiums, manufacturing, distribution, and other customers, Xtract One is recognized as a market leader delivering the highest security in combination with the best individual experience. For more information, visit www.xtractone.com or connect on Facebook, X, and LinkedIn.

About Threat Detection Systems
Xtract One solutions, when properly configured, deployed, and utilized, are designed to help enhance safety and reduce threats. Given the wide range of potential threats in today’s world, no threat detection system is 100% effective. Xtract One solutions should be utilized as one element in a multilayered approach to physical security.

Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance and customer contracts, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, but are not limited to, the risks detailed from time to time in the continuous disclosure filings made by the Company with securities regulations. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information, please contact:
Xtract One Inquiries: info@xtractone.com, http://www.xtractone.com
Investor Relations: Mark Kuindersma, LodeRock Advisors, mark.kuindersma@loderockadvisors.com, 519-501-0545
Media Contact: Kristen Aikey, JMG Public Relations, kristen@jmgpr.com, 212-206-1645

CALGARY, Alberta, Oct. 19, 2026 (GLOBE NEWSWIRE) — Northern Discovery Metals Inc. (CSE: NOR) (FSE: M1V0) (“Northern Discovery” or the “Company”) is pleased to announce a non-brokered private placement of non-flow-through units (“NFT Units”) and flow-through units (“FT Units”), respectively, for aggregate gross proceeds of up to C$1,500,000 (collectively, the “Offering”).

The NFT Units will be offered at a price of C$0.75 per NFT Unit, for gross proceeds of up to C$1,000,000, and each will be comprised of one common share of the Company (each, a “Share”) and one-half of one Share purchase warrant of the Company (each such whole warrant, a “NFT Warrant”). Each NFT Warrant will entitle the holder to acquire one Share (each, a “NFT Warrant Share”) at an exercise price of C$0.95 for a period of 24 months.

The FT Units will be offered at a price of C$0.90 per FT unit, for gross proceeds of up to C$500,000, and each will be comprised of one common share of the Company to be issued as a “flow-through share” within the meaning of the Income Tax Act (Canada) (the “Tax Act”) (each, a “FT Share”) and one-half of one transferable common share purchase warrant of the Company (each such whole warrant, a “FT Warrant”). Each FT Warrant will entitle the holder to acquire one non-flow-through common share of the Company (each, a “FT Warrant Share”) at an exercise price of C$1.10 for a period of 24 months.

The Company intends to use the net proceeds from the sale of the NFT Units for exploration expenses in respect of the Company’s exploration projects, and for general working capital purposes, including investor relations activities.

The Company intends to use the proceeds from the sale of the FT Shares to incur eligible “Canadian exploration expenses” that are intended to qualify as “flow-through mining expenditures”, as those terms are defined in the Tax Act.

The Offering is expected to close on or about November 16, 2026. Closing of the Offering is subject to the receipt of all necessary corporate and regulatory approvals, including approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the applicable date of issuance.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration under the U.S. Securities Act and applicable U.S. state securities laws or an available exemption from those registration requirements.

About Northern Discovery Metals Inc.

Northern Discovery Metals Inc. is a mineral exploration company focused on the acquisition, exploration and advancement of mineral properties in Canada. The Company is exploring for copper at its Vent Copper Project on Vancouver Island, British Columbia. Northern Discovery Metals intends to advance the Vent Copper Project through systematic exploration and evaluation of its mineral potential.

On Behalf of the Board of Directors

Jared Suchan

Chief Executive Officer and Director

Phone: (604) 294-3020

Email: info@northerndiscoverymetals.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this news release constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements regarding the Offering, the anticipated gross proceeds of the Offering, the intended use of proceeds, the Company’s exploration plans and objectives, the incurrence and renunciation of qualifying expenditures, the timing of closing of the Offering and the receipt of required approvals. Such forward-looking information is identified by words such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “will”, “may”, “could” and similar expressions. Forward-looking information is based on management’s current expectations and assumptions.

In particular, this press release contains forward-looking information relating to, among other things, the Offering, including the total proceeds of the NFT Units and FT Units, the use of proceeds, including the planned exploration at the Company’s mineral properties, the intended use of the gross proceeds from the FT Shares to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures”, the timing and amount of the renunciation of such expenses to purchasers of the FT Shares, and the closing (including the proposed closing date) of the Offering. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that the Company will close the Offering on the timeline anticipated, will raise the anticipated amount of gross proceeds from the Offering, will use the proceeds of the Offering as anticipated, and will incur and renounce eligible expenses in the amounts and within the time periods required under the Tax Act. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company’s management, there can be no assurance that any conclusions or forecasts will prove to be accurate.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information, including risks that the Offering may not close as contemplated or at all, that anticipated proceeds may not be raised, that regulatory approvals may not be obtained in a timely manner, that the Company may not use proceeds as anticipated, risks relating to mineral exploration and development, commodity prices, market conditions, availability of financing, tax law changes affecting flow-through shares, permitting and regulatory matters, environmental and title risks, and other risks disclosed in the Company’s public filings. Readers are cautioned not to place undue reliance on forward-looking information. Forward-looking information is made as of the date of this news release and the Company undertakes no obligation to update such information except as required by applicable law.

The CSE has neither approved nor disapproved the information contained herein.

Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role

VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced the appointment of Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026.

Mr. Hoffman takes over in place of Dr. Jacob Lalezari, who had served as Chief Executive Officer since November 2023. Dr. Lalezari will remain with CytoDyn as Head of Research and Translational Sciences, where he will focus on identifying and advancing new opportunities for leronlimab in solid-tumor oncology. The leadership transition comes as CytoDyn prepares for its next phase of clinical development, with a focus on advancing its oncology pipeline, pursuing regulatory milestones and exploring potential strategic partnerships.

“Robert’s expertise is aligned with what’s next for CytoDyn as we look to 2027 as a year of clinical results, regulatory progress, and renewed partnering opportunities,” said Dr. Lalezari. “While our team executes the business plan to build on the very promising results from the CLOVER study, I will focus on identifying new opportunities for possible pursuits in solid-tumor oncology.”

“We are entering a transformational period for the Company, with opportunities to build on the scientific and clinical progress achieved in recent years,” said Mr. Hoffman. “Jay has played an instrumental role in advancing the Company and helping establish a clearer path forward for leronlimab. I am grateful for his leadership and look forward to continuing to work closely with him as we focus on clinical execution, financial discipline and positioning CytoDyn for its next stage of growth.”

The Board of Directors appointed Mr. Hoffman as Chief Executive Officer in consultation with Dr. Lalezari, who supports the transition and intends to continue to support the Company’s scientific efforts. In addition to assuming the CEO role, Mr. Hoffman will continue to serve as the principal accounting officer of the Company.

About Robert E. Hoffman

The Board of Directors appointed Robert E. Hoffman as the Company’s Chief Executive Officer, effective October 20, 2026. Mr. Hoffman first joined CytoDyn on May 15, 2025, originally serving as its Chief Financial Officer. Mr. Hoffman is an industry veteran with decades of financial and leadership experience, having served in a number of biotech executive and board roles. Most recently, he was the President, CEO, interim Chief Financial Officer and Chairperson of the board of directors of Kintara Therapeutics, Inc. Prior to that, he served as Chief Financial Officer and Senior Vice President of Heron Therapeutics, Inc., Chief Financial Officer and Executive Vice President of Innovus Pharmaceuticals, Inc. and Chief Financial Officer of AnaptysBio, Inc. Mr. Hoffman started his career at Arena Pharmaceuticals, Inc., rising through the ranks to Senior Vice President, Finance and Chief Financial Officer. Mr. Hoffman currently serves on the board of directors of TuHURA Biosciences and Fibrobiologics, Inc., and has previously served as a director of several public and private life sciences companies, including Esperion Therapeutics, Inc., ASLAN Pharmaceuticals Limited, Saniona AB, Kura Oncology, Inc., CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Aravive, Inc.

Mr. Hoffman is a former member of the steering committee of the Association of Bioscience Financial Officers. He also formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standards Board from 2010 to 2020. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.

About CytoDyn

CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

Note Regarding Forward-Looking Statements

This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.

Corporate Contact
CytoDyn Inc.
ir@cytodyn.com

Media Contacts
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com